Related Experiment Video

Updated: Aug 12, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K

Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations

Natalie C Ward1, Gerald F Watts2, Warrick Bishop3

  • 1Dobney Hypertension Centre, Medical School, University of Western Australia, Perth, WA, Australia.

Heart, Lung & Circulation
|January 27, 2023
PubMed

Insights

Elevated lipoprotein(a) [Lp(a)] is a key risk factor for cardiovascular diseases. Guidelines recommend targeted screening and risk management for patients with high Lp(a) levels.

Area of Science:

  • Cardiology
  • Genetics
  • Preventive Medicine

Background:

  • Elevated lipoprotein(a) [Lp(a)] is an independent, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD).
  • Lp(a) levels are influenced by genetics, ethnicity, hormones, and renal function, necessitating careful consideration during measurement.
  • Accurate Lp(a) measurement requires apo(a)-isoform independent assays reporting results in molar units (nmol/L).

Purpose of the Study:

  • To provide guidance for cardiologists and specialists on managing adult patients with elevated Lp(a).
  • To outline recommended screening strategies and risk stratification approaches for elevated Lp(a).
  • To detail therapeutic interventions for patients with elevated Lp(a) and associated cardiovascular risk.

Main Methods:

  • Review and synthesis of current scientific evidence and clinical guidelines.
  • Development of recommendations for Lp(a) testing, risk assessment, and management.
  • Consideration of existing and emerging therapeutic strategies, including lifestyle modifications, pharmacotherapy, and apheresis.

Main Results:

  • Selective screening for elevated Lp(a) is recommended in high-risk individuals, not universal screening.
  • Testing is advised for patients with premature ASCVD and those at intermediate-to-high ASCVD risk.
  • Elevated Lp(a) should guide risk stratification and treatment intensification, including lipid-lowering therapies and potentially PCSK9 inhibitors.

Conclusions:

  • Management of elevated Lp(a) involves comprehensive risk factor modification, optimizing lipid-lowering therapies, and considering apheresis for progressive ASCVD.
  • New RNA-based therapies targeting Lp(a) are under investigation and may offer future treatment options.
  • Adherence to guidelines ensures optimal patient care and cardiovascular risk reduction in the context of elevated Lp(a).

Keywords:
Atherosclerotic cardiovascular diseaseAustralian Atherosclerosis SocietyCardiovascular riskLipoprotein(a)

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.4K
Quantification of Atherosclerosis in Mice06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

37.9K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
32
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
739
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
35
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
30
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
44